Oxidative stress in Phenylketonuria: Future directions

Journal of Inherited Metabolic Disease

Volumn 35, Issue 3, 2012, Pages 381-398

  Rocha, Júlio César ^a   Martins, Maria João ^b  

^a INSA IP ^*  (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CARNITINE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MINERAL; PHENYLALANINE; SELENIUM; UBIDECARENONE; VITAMIN; ZINC;

CARDIOVASCULAR DISEASE; DIET THERAPY; FOLLOW UP; FRUIT; HUMAN; METABOLIC REGULATION; NUTRITIONAL DEFICIENCY; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHENYLKETONURIA; PREVALENCE; PROTEIN RESTRICTION; REVIEW; RISK FACTOR; VEGETABLE;

ADOLESCENT; ADULT; ANTIOXIDANTS; CHILD; CHILD, PRESCHOOL; DIET THERAPY; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; FREE RADICALS; HUMANS; INFANT, NEWBORN; MIDDLE AGED; OXIDATIVE STRESS; PHENYLALANINE; PHENYLKETONURIAS; RISK;

EID: 84863315229     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9417-2     Document Type: Review

References (97)

1. Ando K, Fujita T (2009) Metabolic syndrome and oxidative stress. Free Radic Biol Med 47:213-218
2. Artuch R, Vilaseca MA, Moreno J, Lambruschini N, Cambra FJ, Campistol J (1999) Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am J Clin Nutr 70:892-895 (Pubitemid 29512916)
3. Artuch R, Colome C, Vilaseca MA et al. (2001) Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria. J Inherit Metab Dis 24:359-366 (Pubitemid 32677516)
4. Artuch R, Colome C, Sierra C et al. (2004) A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 37:198-203 (Pubitemid 38221567)
5. Aviram M, Kaplan M, Rosenblat M, Fuhrman B (2005) Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol: 263-300
6. Bao B, Prasad AS, Beck FW et al. (2010) Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 91:1634-1641
7. Barretto JR, Silva LR, Leite ME et al. (2008) Poor zinc and selenium status in phenylketonuric children and adolescents in Brazil. Nutr Res 28:208-211 (Pubitemid 351452063)
8. Bergamini CM, Gambetti S, Dondi A, Cervellati C (2004) Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10:1611-1626 (Pubitemid 38559774)
9. Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417-1427
10. Bullon P, Morillo JM, Ramirez-Tortosa MC, Quiles JL, Newman HN, Battino M (2009) Metabolic syndrome and periodontitis: is oxidative stress a common link? J Dent Res 88:503-518
11. Butler JA, Beilstein MA, Whanger PD (1989) Influence of dietary methionine on the metabolism of selenomethionine in rats. J Nutr 119:1001-1009 (Pubitemid 19207413)
12. Campistol J, Perez-Duenas B, Montero R, Artuch R, Conill J, Vilaseca MA (2006) Coenzyme Q10 deficiency seems to be implicated in the pathophysiology of tremor in patients with phenylketonuria. J Inherit Metab Dis 29(suppl 1):96
13. Camps J, Marsillach J, Joven J (2009) The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 46:83-106
14. Castillo M, Zafra MF, Garcia-Peregrin E (1988) Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem Res 13:551-555
15. Castillo M, Iglesias J, Zafra MF, Garcia-Peregrin E (1991a) Inhibition of chick brain cholesterogenic enzymes by phenyl and phenolic derivatives of phenylalanine. Neurochem Int 18:171-174
16. Castillo M, Martinez-Cayuela M, Zafra MF, Garcia-Peregrin E (1991b) Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis. Mol Cell Biochem 105:21-25
17. Colomé C, Artuch R, Lambruschini N, Cambra FJ, Campistol J, Vilaseca M (2001) Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment? Clin Biochem 34:373-376 (Pubitemid 32777845)
18. Colomé C, Artuch R, Vilaseca MA et al. (2002) Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin Biochem 35:81-84 (Pubitemid 34286585)
19. Colomé C, Artuch R, Vilaseca MA et al. (2003) Lipophilic antioxidants in patients with phenylketonuria. Am J Clin Nutr 77:185-188 (Pubitemid 36015390)
20. Craig WJ, Mangels AR (2009) Position of the American Dietetic Association: vegetarian diets. J Am Diet Assoc 109:1266-1282
21. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26:1001-1043
22. de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ (2010) Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab 99(Suppl 1):S86-S89
23. DiSilvestro RA, Blostein-Fujii A (1997) Moderate zinc deficiency in rats enhances lipoprotein oxidation in vitro. Free Radic Biol Med 22:739-742 (Pubitemid 27043412)
24. Efrat M, Aviram M (2010) Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. Adv Exp Med Biol 660:153-166
25. Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E (2010) Suboptimal outcomes in patients with PKU treated early with diet al.one: revisiting the evidence. Mol Genet Metab 101:99-109
26. Farbstein D, Kozak-Blickstein A, Levy AP (2010) Antioxidant vitamins and their use in preventing cardiovascular disease. Molecules 15:8098-8110
27. Feillet F, Agostoni C (2010) Nutritional issues in treating phenylketonuria. J Inherit Metab Dis 33:659-664
28. Fernandes CG, Leipnitz G, Seminotti B et al. (2010) Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats. Cell Mol Neurobiol 30:317-326
29. Fisberg RM, Da Silva-Femandes ME, Fisberg M, Schmidt BJ (1999) Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria. Nutrition 15:449-452 (Pubitemid 29279607)
30. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP (2008) Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23:370-378 (Pubitemid 351787103)
31. Fritz IB, Arrigoni-Martelli E (1993) Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci 14:355-360 (Pubitemid 23308758)
32. Furukawa S, Fujita T, Shimabukuro M et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761 (Pubitemid 40385531)
33. Garin MC, Kalix B, Morabia A, James RW (2005) Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 90:2264-2269 (Pubitemid 40586272)
34. Getz GS, Reardon CA (2004) Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15:261-267 (Pubitemid 38716558)
35. Gropper SS, Gropper DM, Acosta PB (1993) Plasma amino acid response to ingestion of L-amino acids and whole protein. J Pediatr Gastroenterol Nutr 16:143-150 (Pubitemid 23063026)
36. Güllçin I (2006) Antioxidant and antiradical activities of L-carnitine. Life Sci 78:803-811 (Pubitemid 43082302)
37. Haldar S, Rowland IR, Barnett YA et al. (2007) Influence of habitual diet on antioxidant status: a study in a population of vegetarians and omnivores. Eur J Clin Nutr 61:1011-1022 (Pubitemid 47202440)
38. Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine. Clarendon Press, Oxford
39. Hansel B, Kontush A, Bonnefont-Rousselot D, Bruckert E, Chapman MJ (2006) Alterations in lipoprotein defense against oxidative stress in metabolic syndrome. Curr Atheroscler Rep 8:501-509 (Pubitemid 44697804)
40. Hargreaves IP (2007) Coenzyme Q10 in phenylketonuria and mevalonic aciduria. Mitochondrion 7(Suppl):S175-S180 (Pubitemid 46722289)
41. Hargreaves IP, Heales SJ, Briddon A, Land JM, Lee PJ (2002) Blood mononuclear cell coenzyme Q10 concentration and mitochondrial respiratory chain succinate cytochrome-c reductase activity in phenylketonuric patients. J Inherit Metab Dis 25:673-679 (Pubitemid 36416637)
42. Herbert V (1994) The antioxidant supplement myth. Am J Clin Nutr 60:157-158
43. Holvoet P, De Keyzer D, Jacobs DR (2008a) Oxidized LDL and the metabolic syndrome. Future Lipidol 3:637-649
44. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr (2008b) Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299:2287-2293 (Pubitemid 351724395)
45. Hopps E, Noto D, Caimi G, Averna MR (2010) A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 20:72-77
46. Jochum F, Terwolbeck K, Meinhold H, Behne D, Menzel H, Lombeck I (1997) Effects of a low selenium state in patients with phenylketonuria. Acta Paediatr 86:775-777 (Pubitemid 27327132)
47. Key TJ, Appleby PN, Rosell MS (2006) Health effects of vegetarian and vegan diets. Proc Nutr Soc 65:35-41 (Pubitemid 43259982)
48. Kyprianou N, Murphy E, Lee P, Hargreaves I (2009) Assessment of mitochondrial respiratory chain function in hyperphenylalaninaemia. J Inherit Metab Dis 32:289-296
49. Lindsay DG, Astley SB (2002) European research on the functional effects of dietary antioxidants - EUROFEDA. Mol Aspects Med 23:1-38 (Pubitemid 34669880)
50. Lombeck I, Menzel H, Steiner G, Kasperek K (1982) Selenium supplementation: plasma glutathione peroxidase an indicator of selenium intake. Klin Padiatr 194:303-305 (Pubitemid 12067865)
51. Lonnerdal B (1997) Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Physiol Rev 77:643-669 (Pubitemid 27328736)
52. Lu J, Holmgren A (2009) Selenoproteins. J Biol Chem 284:723-727
53. MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW (2003) Free use of fruits and vegetables in phenylketonuria. J Inherit Metab Dis 26:327-338 (Pubitemid 37045440)
54. Macdonald A, Rocha JC, van Rijn M, Feillet F (2011) Nutrition in phenylketonuria. Mol Genet Metab
55. Martindale JL, Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192:1-15 (Pubitemid 34587382)
56. McCord JM (2000) The evolution of free radicals and oxidative stress. Am J Med 108:652-659 (Pubitemid 30336605)
57. Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR (2007) Metaanalysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 17:91-101 (Pubitemid 46889563)
58. Ng CJ, Wadleigh DJ, Gangopadhyay A et al. (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449
59. Pardridge WM (1977) Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem 28:103-108 (Pubitemid 8022771)
60. Prasad AS (2009) Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr 12:646-652
61. Prasad AS, Bao B, Beck FW, Kucuk O, Sarkar FH (2004) Antioxidant effect of zinc in humans. Free Radic Biol Med 37:1182-1190 (Pubitemid 39296743)
62. Précourt LP, Amre D, Denis MC et al. (2010) The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214:20-36
63. Ribas GS, Sitta A, Wajner M, Vargas CR (2011) Oxidative stress in phenylketonuria: what is the evidence? Cell Mol Neurobiol 31:653-662
64. Rizzo M, Kotur-Stevuljevic J, Berneis K et al. (2009) Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 153:217-223
65. Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH (2000) Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr 136:545-547 (Pubitemid 30469600)
66. Rocha JC, Martel F (2009) Large neutral amino acids supplementation in phenylketonuric patients. J Inherit Metab Dis 32:472-480
67. Sanayama Y, Nagasaka H, Takayanagi M, et al. (2011) Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol Genet Metab
68. Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou- Tsagarakis S (1990) Serum carnitine level in phenylketonuric children under dietary control in Greece. Acta Paediatr Scand 79:930-934 (Pubitemid 20333500)
69. Schulpis KH, Tsakiris S, Karikas GA, Moukas M, Behrakis P (2003) Effect of diet on plasma total antioxidant status in phenylketonuric patients. Eur J Clin Nutr 57:383-387 (Pubitemid 36240495)
70. Schulpis KH, Karakonstantakis T, Bartzeliotou A, Karikas GA, Papassotiriou I (2004) The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet. Clin Nutr 23:401-407 (Pubitemid 38811678)
71. Schulpis KH, Tsakiris S, Traeger-Synodinos J, Papassotiriou I (2005) Low total antioxidant status is implicated with high 8-hydroxy-2- deoxyguanosine serum concentrations in phenylketonuria. Clin Biochem 38:239-242 (Pubitemid 40222323)
72. Schulpis KH, Bartzeliotou A, Tsakiris S, Gounaris A, Papassotiriou I (2007) Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet. Eur J Clin Nutr 61:803-808 (Pubitemid 47232360)
73. Schulpis KH, Papastamataki M, Stamou H, Papassotiriou I, Margeli A (2010) The effect of diet on total antioxidant status, ceruloplasmin, transferrin and ferritin serum levels in phenylketonuric children. Acta Paediatr 99:1565-1570
74. Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Sly WS (eds) The metabolic & molecular bases of inherited disease, vol 2, 8th edn. McGraw-Hill, New York, pp 1667-1724
75. Seifried HE, Anderson DE, Fisher EI, Milner JA (2007) A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem 18:567-579 (Pubitemid 47214661)
76. Sierra C, Vilaseca MA, Moyano D et al. (1998) Antioxidant status in hyperphenylalaninemia. Clin Chim Acta 276:1-9 (Pubitemid 28386824)
77. Sirtori LR, Dutra-Filho CS, Fitarelli D et al. (2005) Oxidative stress in patients with phenylketonuria. Biochim Biophys Acta 1740:68-73 (Pubitemid 40692700)
78. Sitta A, Barschak AG, Deon M et al. (2006) Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis 21:287-296 (Pubitemid 46018234)
79. Sitta A, Barschak AG, Deon M et al. (2009a) Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int J Dev Neurosci 27:243-247
80. Sitta A, Barschak AG, Deon M et al. (2009b) L-carnitine blood levels and oxidative stress in treated phenylketonuric patients. Cell Mol Neurobiol 29:211-218
81. Sitta A, Manfredini V, Biasi L et al. (2009c) Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients. Mutat Res 679:13-16
82. Sitta A, Vanzin CS, Biancini GB et al. (2011) Evidence that Lcarnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients. Cell Mol Neurobiol 31:429-436
83. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40 (Pubitemid 43227479)
84. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84 (Pubitemid 44566469)
85. van Bakel MM, Printzen G, Wermuth B, Wiesmann UN (2000) Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am J Clin Nutr 72:976-981
86. van Spronsen FJ, Enns GM (2010) Future treatment strategies in phenylketonuria. Mol Genet Metab 99(Suppl 1):S90-S95
87. van Spronsen FJ, Hoeksma M, Reijngoud DJ (2009) Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 32:46-51
88. Wajner M, Latini A, Wyse AT, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427-448 (Pubitemid 39140134)
89. Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16:41-45 (Pubitemid 38923500)
90. Walter JH, White FJ, Hall SK et al. (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360:55-57 (Pubitemid 34756494)
91. Weber C, Bysted A, Hllmer G (1997a) The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res 67:123-129 (Pubitemid 27176891)
92. Weber C, Bysted A, Holmer G (1997b) Coenzyme Q10 in the diet- daily intake and relative bioavailability. Mol Aspects Med 18 (Suppl):S251-S254
93. Wilke BC, Vidailhet M, Favier A et al. (1992) Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. Clin Chim Acta 207:137-142
94. Willett WC, MacMahon B (1984a) Diet and cancer-an overview. N Engl J Med 310:633-638
95. Willett WC, MacMahon B (1984b) Diet and cancer-an overview (second of two parts) . N Engl J Med 310:697-703 (Pubitemid 14164646)
96. Witztum JL, Steinberg D (2001) The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovas Med 11:93-102 (Pubitemid 33070331)
97. Young IS, Woodside JV (2001) Antioxidants in health and disease. J Clin Pathol 54:176-186 (Pubitemid 32205036)